6′-bromo marchantin C | 1366642-09-2

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物
• 英文名称: 6′-bromo marchantin C
• 英文别名: 18-Bromo-2,15-dioxapentacyclo[22.2.2.13,7.110,14.016,21]triaconta-1(26),3,5,7(30),10(29),11,13,16(21),17,19,24,27-dodecaene-4,17-diol
• CAS: 1366642-09-2
• 化学式: C₂₈H₂₃BrO₄
• 分子量: 503.392
• InChiKey: XYFTYLWAZZXGIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  33
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  marchantin C 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以9%的产率得到15,18-Etheno-2,6:9,13-dimetheno-1,14-benzodioxacyclodocosin-12,24-diol, 22-bromo-7,8,19,20-tetrahydro-
  参考文献：
  名称：

  Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents

  摘要：

  Based on the core skeleton of the total synthesized bisbibenzyl marchantin C, riccardin D and plagiochin E, a series of brominated and aminomethylated derivatives of above three bisbibenzyls have been synthesized and their cytotoxic activity against KB, MCF-7 and PC3 cell lines has been preliminary evaluated. The bio-test results revealed that the brominated derivatives 21, 22, 24, 25 and 28 exhibited excellent antiproliferative activity, with IC50 value lower than their parent compounds. As a most potent microtubule depolymerization agent, compound 28 was found to arrest cells at the G(2)/M phase of the cell cycle as determined by the flow cytometry assay in PC3 cell line. The remarkable biological profile and novel structure of these bisbibenzyl derivatives make them possible as promising candidates for clinical development as chemotherapeutic agents. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.02.004

文献信息

• Design, synthesis and biological evaluation of novel macrocyclic bisbibenzyl analogues as tubulin polymerization inhibitors
  作者：Bin Sun、Lin Li、Qing-wen Hu、Fei Xie、Hong-bo Zheng、Huan-min Niu、Hui-qing Yuan、Hong-xiang Lou

  DOI：10.1016/j.ejmech.2016.06.007

  日期：2016.10

  analysis and a tubulin polymerization assay in HCC1482 cells. The binding mode of compound 88 to tubulin was also investigated utilizing a molecular docking study. In conclusion, the present study improves our understanding of the action of bisbibenzyl-based tubulin polymerization inhibitors and provides a new molecular scaffold for the further development of antitumor agents that target tubulin.

  设计，合成了一系列新颖的大环双联二苄基类似物，并对其体外抗增殖活性进行了评估。所有化合物均在包括多药耐药表型在内的五种人类癌细胞系中进行了测试。在这些新的分子，化合物88，92和94表现出优异的抗癌活性针对Hela细胞，K562，HCC1428，HT29，和PC-3 /文件的细胞系，具有平均IC 50值范围为2.23μM到3.86μM，和更有效的比亲本化合物马可汀C的效力要强于阳性对照阿霉素。此外，化合物88的作用机理通过在HCC1482细胞中的细胞周期分析和微管蛋白聚合测定法研究了TGF-β。还利用分子对接研究来研究化合物88与微管蛋白的结合模式。总之，本研究提高了我们对基于双联苄基微管蛋白聚合抑制剂作用的理解，并为靶向微管蛋白的抗肿瘤药物的进一步开发提供了新的分子支架。